Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 studyAntoîne Italiano, Vincent Ribrag, Carlo Lucchesi et al.|The Lancet Oncology|2018Cited by 614
Membrane Association and Protein Conformation of α-Synuclein in Intact NeuronsPamela J. McLean, Bradley T. Hyman, Hibiki Kawamata et al.|Journal of Biological Chemistry|2000Cited by 239
Identification of a CARM1 Inhibitor with Potent In Vitro and In Vivo Activity in Preclinical Models of Multiple MyelomaAllison E. Drew, Scott Ribich|Scientific Reports|2017Cited by 136